RE: deal28 Nov 2019 07:25
IMM is giving up too much of the potential value in Lupuzor. The US is potentially by far the biggest market for the drug and if it is approved the CNRS will be the main beneficiary not IMM:
"Through this partnership, CNRS will be entitled to receive from ImmuPharma, low double-digit royalty payments of monies received by ImmuPharma from Avion through the Licence and Development Agreement."
I guess there wasn't a better deal on the table but I think IMM would have done better to have raised funds for another phase III trial itself. No deal is better than a bad deal.